Dynamic Whole Body PET/ MRI
Key facts
- Who runs it
- British Columbia Cancer Agency
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Aug 2025
- Expected to end
- Sept 2028
- Type of study
- Observational
- Treatments tested
- 68Ga-HTK03149
- Record updated
- 8 January 2025
- Why it stopped
- Study never initiated, should have been removed prior to last update.
Who can take part
- Age
- 19 years to 99 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Subjects with biopsy-proven high risk prostate cancer (UCSF/CAPRA score 6 or higher) scheduled for radical prostatectomy
- Able to not use the washroom for the duration of the dynamic imaging scanning
- Eastern Cooperative Oncology Group performance status of 2 or less
- Able to lie supine for the required duration of the scans
Who cannot take part
- Subjects with severe renal disease or acutely deteriorating renal function (eGRF<30 mL/min)
- Meet the exclusion criteria for the appropriate standard of care imaging
- Experience claustrophobia
- Subjects may not take part in this study if they have a pacemaker, an implanted defibrillator, or certain other implanted electronic or metallic devices, shrapnel, or other metal
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Prostate cancer is the third most common cause of cancer death in men. Most patients with localized prostate cancer will be cured with surgery or radiation therapy, but up to 35% of patients will have their prostate cancer return.Current conventional imaging modalities have limitations particularly at low prostate specific antigen levels. This study proposes to use 68Ga-HTK03149 Dynamic Whole Body (DWB) Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) scans which targets prostate-specific membrane antigens (PSMA) to detect where in the body the prostate cancer has recurred.
The group in the trial
- 68Ga-HTK03149 PET/MRI DWB scan
All participants will undergo the same procedures listed in "Detailed Description" in the protocol section.
Treatment: 68Ga-HTK03149
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dynamic Whole Body Positron Emission Tomography/ Magnetic Resonance Imaging
- Record updated
- 8 January 2025